经肝动脉化疗栓塞术联合射频消融治疗原发性肝癌的现状

吕天石; 邹英华; 王健; 宋莉

doi:10.3969/j.issn.1001-5256.2016.01.007

经肝动脉化疗栓塞术联合射频消融治疗原发性肝癌的现状

DOI: 10.3969/j.issn.1001-5256.2016.01.007

北京大学第一医院介入血管外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2492
- HTML全文浏览量: 13
- PDF下载量: 475
- 被引次数: 0
出版历程
- 收稿日期: 2015-11-09
- 出版日期: 2016-01-20

Current status of transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of primary liver cancer

Department of Interventional Radiology and Vascular Surgery,Peking University First Hospital

摘要

摘要: 近年来在原发性肝癌治疗领域中新兴治疗方法层出不穷,但由于病变多发生于进展期肝病或肝硬化的基础上,导致原发性肝癌仍然是一种难治性恶性肿瘤。外科手术切除及肝移植虽是根治性治疗方法,但由于移植相关问题的复杂性及原发性肝癌本身的隐匿性,使得上述两种治疗方法并不能适用于大多数患者。而近些年随着设备和技术水平的提高,原发性肝癌的介入治疗得到了越来越多的重视,这其中应用最为广泛的就是经肝动脉化疗栓塞术(TACE)和经皮肝穿刺射频消融(RFA)。主要讨论上述两种介入疗法联合应用治疗原发性肝癌的有效性、可行性,以及近年来介入治疗在原发性肝癌治疗领域的研究进展。
- 肝肿瘤 /
- 化学栓塞,治疗性 /
- 导管消融术 /
- 治疗
Abstract: In recent years,more and more therapeutic methods have been applied for the treatment of primary liver cancer; however,since most lesions develop from progressive liver disease or liver cirrhosis,primary liver cancer is still a refractory malignant tumor. Although surgical resection and liver transplantation are radical therapeutic methods,they are not applicable to most patients due to complex issues related to transplantation and insidious onset of such disease. With the improvement in equipment and technology,the interventional therapies for primary liver cancer have been taken more seriously,especially transcatheter arterial chemoembolization and percutaneous radiofrequency ablation. This article investigates the effect and feasibility of the combination of these two therapies for primary liver cancer and introduces the research advances in interventional therapy for primary liver cancer.
- liver neoplasms /
- chemoembolization,therapeutic /
- catheter ablation /
- therapy

HTML全文

参考文献(66)

[1]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012update[J].Hepatol Int,2012,6(3):531-561.

[2]OMATA M,KANDA T,YU ML,et al.APASL consensus statements and management algorithms for hepatitis C virus infection[J].Hepatol Int,2012,6(2):409-435.

[3]YOSHIZAWA H,TANAKA J,MIYAKAWA Y.National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population[J].Intervirology,2006,49(1-2):7-17.

[4]KANDA T,IMAZEKI F,YOKOSUKA O.New antiviral therapies for chronic hepatitis C[J].Hepatol Int,2010,4(3):548-561.

[5] JEMAL A,BRAY F,CENTER MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.

[6]EL-SERAG HB,RUDOLPH KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology,2007,132(7):2557-2576.

[7]ZHAO P,DAI M,CHEN W,et al.Cancer trends in China[J].Jpn J Clin Oncol,2010,40(4):281-285.

[8]GREENE FL,SOBIN LH.The staging of cancer:a retrospective and prospective appraisal[J].CA Cancer J Clin,2008,58(3):180-190.

[9]LEUNG TW,TANG AM,ZEE B,et al.Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system,the Okuda staging system,and the Cancer of the Liver Italian Program staging system:a study based on 926 patients[J].Cancer,2002,94(6):1760-1769.

[10]GRIECO A,POMPILI M,CAMINITI G,et al.Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:comparison of Okuda,CLIP,and BCLC staging systems in a single Italian centre[J].Gut,2005,54(3):411-418.

[11]CILLO U,VITALE A,GRIGOLETTO F,et al.Prospective validation of the Barcelona Clinic Liver Cancer staging system[J].J Hepatol,2006,44(4):723-731.

[12]MAKUUCHI M,KOSUGE T,TAKAYAMA T,et al.Surgery for small liver cancers[J].Semin Surg Oncol,1993,9(4):298-304.

[13]YAMAZAKI S,TAKAYAMA T.Surgical treatment of hepatocellular carcinoma:evidence-based outcomes[J].World J Gastroenterol,2008,14(5):685-692.

[14]SHIINA S,TATEISHI R,IMAMURA M,et al.Percutaneous ethanol injection for hepatocellular carcinoma:20-year outcome and prognostic factors[J].Liver Int,2012,32(9):1434-1442.

[15]SHIINA S,TATEISHI R,ARANO T,et al.Radiofrequency ablation for hepatocellular carcinoma:10-year outcome and prognostic factors[J].Am J Gastroenterol,2012,107(4):569-577;quiz578.

[16]TANAKA K,SHIMADA M,KUDO M.Characteristics of longterm survivors following sorafenib treatment for advanced hepatocellular carcinoma:report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan[J].Oncology,2014,87(Suppl 1):104-109.

[17]LEE YT.Primary carcinoma of the liver:diagnosis,prognosis,and management[J].J Surg Oncol,1983,22(1):17-25.

[18]BORIE F,BOUVIER AM,HERRERO A,et al.Treatment and prognosis of hepatocellular carcinoma:a population based study in France[J].J Surg Oncol,2008,98(7):505-509.

[19]SAKAMOTO M,HIROHASHI S,TSUDA H,et al.Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern[J].Am J Surg Pathol,1989,13(12):1064-1067.

[20]OIKAWA T,OJIMA H,YAMASAKI S,et al.Multistep and multicentric development of hepatocellular carcinoma:histological analysis of 980 resected nodules[J].J Hepatol,2005,42(2):225-229.

[21]TAKAYASU K,ARII S,IKAI I,et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J].Gastroenterology,2006,131(2):461-469.

[22]TAKAYASU K,ARII S,KUDO M,et al.Superselective transarterial chemoembolization for hepatocellular carcinoma.Validation of treatment algorithm proposed by Japanese guidelines[J].J Hepatol,2012,56(4):886-892.

[23]HAN KH,KUDO M,YE SL,et al.Asian consensus workshop report:expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia[J].Oncology,2011,81(Suppl 1):158-164.

[24]GOLFIERI R,GIAMPALMA E,RENZULLI M,et al.Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J].Br J Cancer,2014,111(2):255-264.

[25]LAMMER J,MALAGARI K,VOGL T,et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:results of the PRECISION V study[J].Cardiovasc Intervent Radiol,2010,33(1):41-52.

[26]VOGL TJ,LAMMER J,LENCIONI R,et al.Liver,gastrointestinal,and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads:results from the PRECISION V randomized trial[J].AJR Am J Roentgenol,2011,197(4):w562-w570.

[27]DHANASEKARAN R,KOOBY DA,STALEY CA,et al.Comparison of conventional transarterial chemoembolization(TACE)and chemoembolization with doxorubicin drug eluting beads(DEB)for unresectable hepatocelluar carcinoma(HCC)[J].J Surg Oncol,2010,101(6):476-480.

[28]ANDREANA L,ISGRG,MARELLI L,et al.Treatment of hepatocellular carcinoma(HCC)by intra-arterial infusion of radio-emitter compounds:trans-arterial radio-embolisation of HCC[J].Cancer Treat Rev,2012,38(6):641-649.

[29]VENTE MA,WONDERGEM M,van der TWEEL I et al.Yttrium-90 microsphere radioembolization for the treatment of liver malignancies:a structured meta-analysis[J].Eur Radiol,2009,19(4):951-959.

[30]GAO W,LIU L,TENG GJ,et al.Internal radiotherapy using 32P colloid or microsphere for refractory solid tumors[J].Ann Nucl Med,2008,22(8):653-660.

[31]LAU WY,LEUNG TW,HO SK,et al.Adjuvant intra-arterial lipiodol-iodine-131 for espectable hepatocellular carcinoma:a prospective espectable trial[J].Lancet,1999,353(9155):797-801.

[32]ClinicalT rials.gov.Identifier NCT00956930,chemoembolization versus radioembolization in treating patients with liver cancer that cannot be treated with radiofrequency ablation or surgery[DB/OL].Bethesda:U.S.National Institutes of Health,c2015[2014-11-01].https://www.clinicaltrials.gov/ct2/show/NCT00956930?term=NCT00956930&rank=1.

[33]SIEGHART W,HUCKE F,PINTER M,et al.The ART of decision making:retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma[J].Hepatology,2013,57(6):2261-2273.

[34]HUCKE F,SIEGHART W,PINTER M,et al.The ART-strategy:sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE[J].J Hepatol,2014,60(1):118-126.

[35]YOSHIDA H,ONDA M,TAJIRI T,et al.Treatment of spontaneous ruptured of hepatocellular carcinoma[J].Hepatogastroenterology,1999,46(1):2451-2453.

[36]HSIEH MY,LIN ZY,CHUAUG WL.Serial serum VEGF-A,angiopoietin-2,and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization[J].Kaohsiung J Med Sci,2011,27(8):314-322.

[37]HASEGAWA K,KOKUDO N,SHIINA S,et al.Surgery versus radiofrequency ablation for small hepatocellular carcinoma:Start of a randomized controlled trial(SURF trial)[J].Hepatol Res,2010,40(8):851-852.

[38]LIVRAGHI T,LAZZARONI S,MELONI F.Radiofrequency ablation of hepatocellular carcinoma[J].Eur J Ultrasound,2001,13(2):159-166.

[39]LZZO F,BARNETT C JR,CURLEY SA.Radio frequency ablation of primary and metastatic malignant liver tumors(Review)[J].Adv Surg,2001,35:225-234.

[40] TERATANI T,YOSHIDA H,SHIINA S,et al.Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations[J].Hepatology,2006,43(5):1101-1108.

[41]McG AHAN JP,DODD GD 3rd.Radiofrequency ablation of the liver:current status[J].AJR Am J Gastroenterol,2001,176(1):3-16.

[42] LIVRAGHI T,SOLBIATI L,MELONI MF,et al.Treatment of focal liver tumors with percutaneous radio-frequency ablation:complications encountered in a multicenter study[J].Radiology,2003,226(2):441-451.

[43]MELONI MF,GOLDBERG SN,MOSER V,et al.Colonic perforation and abscess following radiofrequency ablation treatment of hepatoma[J].Eur J Ultrasound,2002,15(1-2):73-76.

[44]WOOD TF,ROSE DM,CHUNG M,et al.Radiofrequency ablation of 231 unresectable hepatic tumors:indications,limitations,and complications[J].Ann Surg Oncol,2000,7(8):593-600.

[45]LIVRAGHI T,GOLDBERG SN,LAZZARONI S,et al.Small hepatocellular carcinoma:treatment with radio-frequency ablation versus ethanol injection[J].Radiology,1999,210(3):655-661.

[46]QIAN CW,CHEN LY,CHEN JY,et al.Ultrasound-guided percutaneous radiofrequency ablation for particular-location liver malignancies[J].Chin J Ultrasonogr,2005,14(9):659-663.(in Chinese)钱超文,陈丽羽,陈俊英,等.部分特殊部位肝恶性肿瘤的超声引导下冷循环射频消融治疗[J].中华超声影像学杂志,2005,14(9):659-663.

[47]ZHAI B,LI XY,LIU C,et al.Radiofrequency ablation for the treatment of primary hepatocellular carcinoma located at hepatic dome[J].J Intervent Radiol,2009,18(5):357-361.(in Chinese)翟博,李晓燕,刘晨,等.膈顶部原发性肝癌的射频消融[J].介入放射学杂志,2009,18(5):357-361.

[48]LI JJ,ZHENG JS,CUI XW,et al.CT-guided radiofrequency ablation of hepatic tumor:an analysis of complications[J].J Intervent Radiol,2009,18(5):367-369.(in Chinese)李建军,郑加生,崔雄伟,等.CT引导下肝肿瘤射频消融治疗的并发症分析[J].介入放射学杂志,2009,18(5):367-369.

[49]HEAD HW,DODD GD 3rd,DALRYMPLE NC,et al.Percutaneous radiofrequency ablation of hepatic tumors against the diaphragm:frequency of diaphragmatic injury[J].Radiology,2007,243(3):877-884.

[50]de BAERE T,DROMAIN C,LAPEYRE M,et al.Artificially induced pneumothorax for percutaneous transthoracic radiofrequency ablation of tumors in the hepatic dome:initial experience[J].Radiology,2005,236(2):666-670.

[51]NAKAI M,SHIRAKI T,HIGASHI K,et al.Low output radiofrequency ablation combined with transcatheter arterial oily-chemoembolization for hepatocellular carcinoma[J].Nippon Igaku Hoshasen Gakkai Zasshi,2005,65(2):124-126.

[52]JI TL,DU XL,LI G,et al.Precutaneous hepatic puncture radio frequency ablation combined with transcatheter arterial embolization(HAE)therapy in the treatment of hepatocellular carcinoma[J].J Mod Oncol,2004,12(6):540-543.(in Chinese)姬统理,杜锡林,李刚,等.肝动脉化疗栓塞术加经皮肝穿刺射频消融术治疗原发性肝癌56例[J].现代肿瘤医学,2004,12(6):540-543.

[53]BUSCARINI L,BUSCARINI E,DISTASI M,et al.Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma[J].Ultraschal Med,1999,20(2):47-51.

[54]TAKAKI H,YAMAKADO K,URAKI J,et al.Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm[J].J Vasc Interv Radiol,2009,20(2):217-224.

[55]SONG L,TONG XQ,WANG J,et al.CT arterioportography and CT arteriography in evaluating therapeutic response of hepatic malignancies after radiofrequency ablation[J].Chin J Interv Imaging Ther,2006,3(5):333-336.(in Chinese)宋莉,佟小强,王健,等.CTAP联合CTA评价肝脏恶性肿瘤射频消融术疗效[J].中国介入影像与治疗学,2006,3(5):333-336.

[56]EGM ANTONUCCIO,R IEZZI,A CONTEGIACOMO,et al.Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization(DEB-TACE)for the treatment of single large hepatocellular carcinoma[C].Vienna:European Society of Radiology,2015.

[57]CHENG BQ,JIA CQ,LIU CT,et al.Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm:a randomized controlled trial[J].JAMA,2008,299(14):1669-1677.

[58]ZHAN FJ,WU PH,ZHAO M,et al.Evaluation of combined percutaneous radio-frequency ablation and percutaneous ethanol injection after transcatheter arterial chemoembolization for hepatocellular carcinoma[J].Chin J Oncol,2005,27(4):248-250.(in Chinese)张福君,吴沛宏,赵明,等.肝动脉栓塞化疗后射频消融联合酒精消融对原发性肝癌的疗效评价[J].中国肿瘤学杂志,2005,27(4):248-250.

[59]CUI Y,CHANG J,ZHOU LY,et al.Efficacy evaluation of percutaneous radiofrequency ablation in combination with transcatheter arterial chemoembolization for large hepatocellular carcinoma[J].Chin J Interv Imaging Ther,2006,3(1):1-4.(in Chinese)崔彦,畅坚,周立艳,等.经皮射频联合肝动脉导管化疗栓塞治疗大肝癌疗效分析[J].中国介入影像与治疗学,2006,3(1):1-4.

[60]YANG W,CHEN MH,WANG MQ,et al.Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment[J].Hepatol Res,2009,39(3):231-240.

[61]KIRIKOSHI H,SAITO S,YONEDA M,et al.Outcome of transarterial chemoembolization monotherapy and in combination with percutaneous ethanol injection or radiofrequency ablation therapy for hepatocellular carcinoma[J].Hepatol Res,2009,39(6):553-562.

[62]KAGAWA T,KOIZUMI J,KOJIMA S,et al.Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma:comparison with surgical resection[J].Cancer,2010,116(15):3638-3644.

[63]FAN WZ,LI JP,YANG JY,et al.Interventional treatmeant for unresectable hepatocellular carcinoma:a systematic review and Meta-analysis[J/CD].Chin Arch General Surg:Electronic Version,2011,5(1):62-67.(in Chinese)范文哲,李家平,杨建勇,等.无法手术切除的肝细胞癌TACE与RFA治疗的Meta分析[J/CD].中华普通外科学文献:电子版,2011,5(1):62-67.

[64]FAN WZ,LI JP,LI HP,et al.Interventional treameant for unresectable hepatocellular carcinoma:a systematic review and Meta-analysis[J].Contemp Med,2009,15(35):677-680.(in Chinese)范文哲,李家平,李鹤平,等.国内无法手术切除的原发性肝癌介入治疗的系统性回顾及Meta分析[J].当代医学,2009,15(35):677-680.

[65]TAKAHASHI S,KUDO M,CHUNG H,et al.Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy[J].Oncology,2007,72(Suppl 1):98-103.

[66]ZHAO S,CHEN XC,LONG QY,et al.Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma:a systematic review and Meta analysis[J].J Intervent Radiol,2013,22(11):908-913.(in Chinese)赵松,陈学春,龙清云,等.经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,22(11):908-913.

施引文献

资源附件(0)

访问统计